The biotechnology company is dedicated to discovering and advancing new medicines that restore vision to patients suffering from retinal diseases, such as Age Related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP), which cause irreversible vision loss in millions of patients worldwide. Their technology platform uses induced-pluripotent stem cells (iPSCs) to manufacture authentic human retinal cells at scale, allowing for the development of a pipeline of best-in-class cell replacement therapies. Opsis Therapeutics is committed to finding a cure for irreversible vision loss and improving the lives of those affected by retinal degenerative diseases.